PrREXULTI®: An adjunctive treatment for MDD with demonstrated efficacy
Primary endpoint
When taken with an antidepressant, adding REXULTI improved depression symptoms, as measured by MADRS at week 6 (clinician-rated).1,2*
A 62% statistically significant greater reduction in depressive symptoms at week 6 as measured by MADRS vs. antidepressant + placebo (in favour of antidepressant + REXULTI 2 mg/day; p=0.0001).1,2
* p<0.01; † p<0.001; ‡ p=0.0001
as
early as week 1
3.12-point
greater reduction for patients treated with antidepressant + REXULTI 2 mg/day vs. antidepressant + placebo at week 6 (p=0.0001)
Adapted from Product Monograph and Thase et al. (incl. Supplementary Material)
DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; LS: least squares; MADRS: Montgomery-Asberg Depression Rating Scale.
Results from a phase 3, 6-week, randomized, double-blind, placebo-controlled fixed-dose trial in adult patients who fulfilled the DSM-IV-TR criteria for MDD, with or without symptoms of anxiety, had an inadequate response to 1–3 prior antidepressant treatment(s) in current episode and an inadequate response during 8 weeks of prospective antidepressant treatment. Patients remained on background antidepressant treatment and were randomized to receive adjunct placebo (n=191) or adjunct REXULTI (0.5 mg/day for week 1, 1 mg/day for week 2, 2 mg/day for week 3 onwards; n=187).
References: 1. REXULTI Product Monograph. Otsuka Pharmaceutical Co., Ltd. 2. Thase ME, Youakim JM, Skuban A et al. Supplementary material. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: A phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9).